A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis

被引：4
|
作者：
Daver, Naval G. [1 ]
Kremyanskaya, Marina [2 ]
O'Connell, Casey [3 ]
Dao, Kim-Hien [4 ]
Oh, Stephen T. [5 ]
Gerds, Aaron T. [6 ]
Verstovsek, Srdan [1 ]
Erickson-Viitanen, Sue [7 ]
Zhou, Feng [7 ]
Assad, Albert [7 ]
Yacoub, Abdulraheem [8 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Mt Sinai Hlth Syst, New York, NY USA
[3] Univ Southern Calif, Los Angeles, CA USA
[4] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[5] Washington Univ, Sch Med, St Louis, MO USA
[6] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[7] Incyte Corp, Wilmington, DE USA
[8] Univ Kansas, Med Ctr, Kansas City, KS 66103 USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-111338
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
353
引用
收藏
页数：3
相关论文
共 50 条
  • [41] A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis
    Couban, Stephen
    Benevolo, Giulia
    Donnellan, William
    Cultrera, Jennifer
    Koschmieder, Steffen
    Verstovsek, Srdan
    Hooper, Gregory
    Hertig, Christian
    Tandon, Maneesh
    Dimier, Natalie
    Malhi, Vikram
    Passamonti, Francesco
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [42] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study
    Rampal, Raajit K.
    Verstovsek, Srdan
    Devlin, Sean M.
    Stein, Eytan M.
    Kadia, Tapan M.
    Mauro, Michael J.
    Pemmaraju, Naveen
    Alvarez, Kelsey
    Ard, Nicole
    Goodman, Tawni
    Marek, Kelly
    Bose, Prithviraj
    BLOOD, 2018, 132
  • [43] Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients With Myelofibrosis: Initial Results of a Phase II Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (01) : 8 - 10
  • [44] Phase 2 study of ruxolitinib in combination with 5-azacitidine in patients with myelofibrosis.
    Masarova, Lucia
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Jabbour, Elias
    Bose, Prithviraj
    Ohanian, Maro
    Zhou, Lingsha
    Pierce, Sherry
    Gergis, Romany
    Borthakur, Gautam
    Estrov, Zeev
    Garcia-Manero, Guillermo
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    Daver, Naval Guastad
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] Phase 2A Study of Copanlisib, a Novel PI3K Inhibitor, in Patients with Indolent Lymphoma
    Dreyling, Martin
    Cunningham, David
    Bouabdallah, Krimo
    Assouline, Sarit
    Van den Neste, Eric
    Vitolo, Umberto
    Giurescu, Marius
    Mappa, Silvia
    Grunert, Julia
    Childs, Barrett H.
    Morschhauser, Franck
    BLOOD, 2014, 124 (21)
  • [46] Efficacy and Safety of Fedratinib in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Results from the Phase 3 Randomized FREEDOM2 Study
    Harrison, Claire N.
    Mesa, Ruben
    Talpaz, Moshe
    Al-Ali, Haifa Kathrin
    Xicoy, Blanca
    Passamonti, Francesco
    Palandri, Francesca
    Benevolo, Giulia
    Vannucchi, Alessandro M.
    Mediavilla, Clemence
    Iurlo, Alessandra
    Kim, InHo
    Brown, Patrick
    Hernandez, Christopher
    Rose, Shelonitda
    Wang, Jia
    Kiladjian, Jean-Jacques
    BLOOD, 2023, 142
  • [47] Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
    Yacoub, Abdulraheem
    Borate, Uma
    Rampal, Raajit K.
    Ali, Haris
    Wang, Eunice
    Gerds, Aaron T.
    Hobbs, Gabriela S.
    Kremyanskaya, Marina
    Winton, Elliott
    O'Connell, Casey
    Goel, Swati
    Oh, Stephen T.
    Schiller, Gary J.
    Assad, Albert
    Erickson-Viitanen, Sue
    Zhou, Feng
    Daver, Naval
    BLOOD, 2022, 140
  • [48] Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis
    Gupta, Vikas
    Harrison, Claire N.
    Hasselbalch, Hans
    Pieri, Lisa
    Koschmieder, Steffen
    Cervantes, Francisco
    Bao, Weichao
    Kalambakas, Stacey
    Atienza, Edric
    Gopalakrishna, Prashanth
    Heidel, Florian H.
    BLOOD, 2015, 126 (23)
  • [49] Correction: Efficacy and safety of a novel dosing strategy for ruxolitinib in the treatment of patients with myelofibrosis and anemia: the REALISE phase 2 study
    Francisco Cervantes
    David M. Ross
    Atanas Radinoff
    Francesca Palandri
    Alexandr Myasnikov
    Alessandro M. Vannucchi
    Pierre Zachee
    Heinz Gisslinger
    Norio Komatsu
    Lynda Foltz
    Francesco Mannelli
    Francesco Passamonti
    Geralyn Gilotti
    Islam Sadek
    Ranjan Tiwari
    Evren Zor
    Haifa Kathrin Al-Ali
    Leukemia, 2021, 35 : 3626 - 3626
  • [50] Phase I/II study to evaluate the safety and efficacy of tenalisib, a novel PI3K δ/γ dual inhibitor in combination with pembrolizumab in patients with relapsed/refractory classical Hodgkin lymphoma.
    Ramchandren, Rod
    Lynch, Ryan C.
    Barde, Prajak J.
    Nair, Ajit
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345